Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Cardiology›Condition·Updated May 5, 2026·v1

HFrEF (Heart Failure with reduced Ejection Fraction)

HFrEF is a high-mortality clinical syndrome (LVEF ≤40 %) driven by neurohormonal maladaptation. Management centers on the 'four pillars' of GDMT (ARNI, BB, MRA, SGLT2i), which should be initiated rapidly and titrated to target doses. Device therapy (ICD/CRT) is indicated if LVEF remains low after 90 days of optimal therapy.

High Evidence177 references·7,492 words·30 min read·v1
HFrEFHeart FailureCardiologyGDMTARNISGLT2 inhibitors

Quick Reference

RxDrug of choiceFour-pillar GDMT: ARNI ([[sacubitril/valsartan]]), Beta-blocker, MRA, and SGLT2 inhibitor
AltAlternativesACE inhibitors or ARBs (if ARNI not tolerated), Vericiguat, Ivabradine, Digoxin, Hydralazine/Isosorbide dinitrate
⊘AvoidNon-dihydropyridine CCBs (Diltiazem, Verapamil), NSAIDs, Thiazolidinediones
DxTest of choiceTransthoracic Echocardiogram (TTE) for LVEF and structural assessment
ScKey scoreKCCQ-12 (Health Status), MAGGIC Score (Mortality Risk), NYHA Classification (Functional Severity)
→When to referLVEF ≤35 % after 90 days GDMT (for ICD/CRT), NYHA Class III-IV despite GDMT, recurrent hospitalizations, or escalating diuretic needs
HFrEF (LVEF ≤40 %) requires rapid initiation of four-pillar GDMT to arrest remodeling and reduce the high risk of mortality and hospitalization.
Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome defined by a left ventricular ejection fraction (LVEF) ≤40%, representing a state of severe myocardial impairment and maladaptive neurohormonal activation. It affects approximately 6.7 million adults in the United States alone, with a prognosis that remains guarded; untreated 5-year mortality often exceeds 50%. The management paradigm has undergone a seismic shift from the sequential addition of drugs to the simultaneous or rapid-sequence initiation of the "four pillars" of guideline-directed medical therapy (GDMT): an ARNI, an evidence-based beta-blocker, a mineralocorticoid receptor antagonist (MRA), and an SGLT2 inhibitor. This foundational regimen, established by landmark trials like PARADIGM-HF and DAPA-HF, reduces all-cause mortality by approximately 73%. Clinical success hinges on early diagnosis via echocardiography and natriuretic peptides, followed by aggressive titration to target doses and timely referral for device or advanced therapies.

Overview and Recommendations

Background

  • •HFrEF — heart failure with LVEF ≤ 40 % — accounts for approximately 50 % of the global heart failure population and carries a 1-year mortality of 17 % at class IV despite optimal therapy.
  • •The four pillars of GDMT (ARNI, beta-blocker, MRA, SGLT2 inhibitor) replaced the legacy ACE-I + BB + diuretic triad following landmark trials such as PARADIGM-HF (2014), DAPA-HF (2019), and EMPEROR-Reduced (2020), which collectively demonstrated that multi-pathway modulation is superior to simple neurohormonal blockade.
  • •Maladaptive activation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system (SNS) drives the central pathophysiology — including eccentric ventricular remodeling, chamber dilation, and progressive fibrosis — while the counter-regulatory natriuretic peptide system is often overwhelmed or degraded by .
  • •Ischemic etiology (coronary artery disease) dominates approximately 60 % of cases, but non-ischemic causes are increasingly recognized, including hypertension, valvular disease, viral , genetic cardiomyopathies, and toxin exposure such as or alcohol.
  • •Prognostic stakes are high, as each heart failure hospitalization serves as a sentinel event for increased mortality; however, cardiac reverse remodeling (improvement in LVEF and reduction in chamber size) is achievable in a significant subset of patients who reach target GDMT doses.
  • •Emerging biomarkers and imaging parameters, such as levels and left atrial (LA) reservoir strain, provide deeper insights into the HFrEF phenotype and help predict the risk of cardiovascular death and recurrent hospitalizations.

Evaluation

  • •Suspect HFrEF in any patient presenting with exertional dyspnea, orthopnea, paroxysmal nocturnal dyspnea, or unexplained fatigue accompanied by peripheral edema.
  • •Examine for specific signs of systemic venous congestion, most notably an elevated (JVP), which is highly specific for increased pulmonary capillary wedge pressure.
  • •Auscultate for a third heart sound (S3 gallop), a hallmark of rapid ventricular filling into a dilated, non-compliant chamber, and assess for displaced apical impulses indicating cardiomegaly.
  • •Order a (TTE) as the gold-standard initial imaging to confirm an LVEF ≤40 %, assess chamber dimensions, and evaluate for secondary or other valvular pathologies.
  • •Measure natriuretic peptides ( or ) to support the diagnosis and establish a prognostic baseline; note that levels may be disproportionately high in or low in patients with obesity.
  • •Obtain a 12-lead to assess for rhythm (e.g., ) and QRS duration; a QRS ≥150 ms with left bundle-branch block (LBBB) morphology is a key threshold for future (CRT) eligibility.
  • •Evaluate renal function (eGFR) and serum potassium (K+) before initiating RAAS inhibitors or MRAs, as baseline hyperkalemia or severe renal impairment may require modified titration strategies.
  • •Screen for iron deficiency, defined as a ferritin <100 μg/L or a transferrin saturation (TSAT) <20 %, which is present in up to 50 % of patients and contributes to functional decline regardless of anemia status.
  • •Consider (CMR) if the etiology remains uncertain after initial workup, particularly to assess for myocardial viability, infiltrative diseases like , or late gadolinium enhancement (LGE) patterns.
  • •Utilize the (KCCQ-12) to quantify patient-reported health status, as lower scores are strongly correlated with higher risks of hospitalization and mortality.

Management

  • •Initiate the four-pillar GDMT simultaneously or in rapid sequence (within 1-2 weeks) to maximize early survival benefits: ARNI + beta-blocker + MRA + SGLT2 inhibitor.
  • •Administer (ARNI) as the preferred first-line RAS inhibitor; start at 49/51 mg BID and titrate to the target dose of 97/103 mg BID as tolerated by blood pressure.
  • •Prescribe an evidence-based beta-blocker once the patient is euvolemic: (target 25-50 mg BID), (target 200 mg daily), or (target 10 mg daily).
  • •Add a mineralocorticoid receptor antagonist (MRA) such as or at 25 mg daily, titrating to 50 mg daily; monitor potassium closely and maintain K+ <5.0 mEq/L.
  • •Initiate an SGLT2 inhibitor, either 10 mg daily or 10 mg daily, regardless of the presence of type 2 diabetes, to provide early hemodynamic and renal protection.
  • •Manage fluid overload with IV loop diuretics (e.g., or ); for refractory congestion, consider the addition of a thiazide-like diuretic or small-volume hypertonic saline.
  • •Add (soluble guanylate cyclase stimulator) starting at 2.5 mg daily and titrating to 10 mg daily for patients with a recent worsening heart failure event despite foundational GDMT.
  • •Consider for patients in sinus rhythm with a resting heart rate ≥70 bpm who are already on maximally tolerated beta-blocker doses.
  • •Administer IV ferric carboxymaltose for patients with iron deficiency (ferritin <100 or TSAT <20 %) to improve functional capacity and reduce the risk of heart failure hospitalizations.
  • •Re-evaluate LVEF after 90 days of optimized GDMT; if LVEF remains ≤35 %, refer for an (ICD) for primary prevention of sudden cardiac death.
  • •Refer for (CRT) in patients with LVEF ≤35 %, NYHA Class II-IV symptoms, and a QRS duration ≥150 ms with LBBB morphology.
  • •Avoid non-dihydropyridine calcium channel blockers (e.g., , ) and most NSAIDs, as these can exacerbate heart failure symptoms and increase the risk of decompensation.
  • •Refer to an advanced heart failure specialist for evaluation of (LVAD) or heart transplantation if the patient remains in NYHA Class III-IV despite optimal therapy.
  • •Monitor for by tracking eGFR and K+; do not reflexively discontinue GDMT for minor, stable declines in renal function (e.g., <30 % increase in creatinine).

Board Review — High Yield

  • •S3 Gallop — Highly specific physical exam finding for HFrEF, representing rapid ventricular filling into a dilated chamber.
  • •Eccentric Remodeling — The structural hallmark of HFrEF, characterized by chamber dilation and wall thinning (vs. concentric hypertrophy in HFpEF).
  • •Neprilysin Inhibition — The mechanism of Sacubitril, which prevents the breakdown of beneficial natriuretic peptides (BNP, ANP).
  • •90-Day Rule — The mandatory period of optimal medical therapy required before considering primary prevention ICD or CRT implantation.
  • •Iron Deficiency — Defined as Ferritin <100 or TSAT <20 %; treatment with IV iron improves symptoms even without anemia.
  • •SGLT2 Inhibitors — Provide mortality benefit in HFrEF regardless of diabetes status and help mitigate MRA-induced hyperkalemia.
  • •LBBB and QRS ≥150ms — The strongest predictors of a positive response to Cardiac Resynchronization Therapy (CRT).
  • •Cardiorenal Syndrome — The bidirectional dysfunction of the heart and kidneys; GDMT (especially SGLT2i) often provides long-term renal protection despite initial eGFR dips.

Deep Dive — Evidence Details

References

  1. [1]

    Li K, Wang X, Qin M et al.. “Optimal Ablation Strategies for Persistent Atrial Fibrillation With Heart Failure: Three-Year Follow-Up of a Prospective Multicenter Randomized Trial.” Circulation. Arrhythmia and electrophysiology (2026). PMID: 41914182 ↗

    L1RCTCited in: Definition, Classification, and Epidemiology, Etiology and Risk Factors, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Management of Comorbidities and Iron Deficiency, Prognosis, Risk Stratification, and Palliative Care
  2. [2]

    Choi KH, Kang D, Kim W et al.. “Discontinuation of Beta-Blocker Therapy after Myocardial Infarction.” The New England journal of medicine (2026). PMID: 41910427 ↗

    L1RCTCited in: Definition, Classification, and Epidemiology
  3. [3]

    Zang H, Jia C, Pan Y et al.. “Left Atrial Volume Index and Left Ventricular Mass Index Determine the Benefits of Spironolactone in Patients With Heart Failure With Preserved Ejection Fraction.” Journal of the American Heart Association (2026). PMID: 41848036 ↗

    L2RCTCited in: Definition, Classification, and Epidemiology
  4. [4]

    Chen X, Liu X, Li R et al.. “Long-Term Outcomes of Left Bundle-Branch Pacing vs Biventricular Pacing in Heart Failure: The HeartSync-LBBP Randomized Clinical Trial.” JAMA cardiology (2026). PMID: 41811342 ↗

    L1RCTCited in: Definition, Classification, and Epidemiology
  5. [5]

    Zimerman A, Dal Forno A, Rohde LE et al.. “Conduction System vs Biventricular Pacing in Heart Failure: The PhysioSync-HF Randomized Clinical Trial.” JAMA cardiology (2026). PMID: 41811324 ↗

    L1RCTCited in: Definition, Classification, and Epidemiology, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Device Therapy: ICD and CRT, Prognosis, Risk Stratification, and Palliative Care
  6. [6]

    Foà A, Vaduganathan M, Claggett BL et al.. “Effect of the cardiac myosin activator omecamtiv mecarbil on ventricular arrhythmias, cardiac arrest, and sudden death in heart failure with reduced ejection fraction: the GALACTIC-HF trial.” European journal of heart failure (2026). PMID: 41771140 ↗

    L1RCTCited in: Definition, Classification, and Epidemiology, Etiology and Risk Factors, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Prognosis, Risk Stratification, and Palliative Care
  7. [7]

    Chimura M, Jhund PS, Henderson AD et al.. “Efficacy of finerenone in patients with heart failure and mildly reduced or preserved ejection fraction: a prespecified analysis of heart rate and heart rhythm in the FINEARTS-HF trial.” European journal of heart failure (2026). PMID: 41771075 ↗

    L1RCTCited in: Definition, Classification, and Epidemiology, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Pharmacological Management: The Four Pillars, Management of Comorbidities and Iron Deficiency, Acute Decompensated Heart Failure (ADHF) in HFrEF, Prognosis, Risk Stratification, and Palliative Care
  8. [8]

    Shen L, Shen L, Cheang I et al.. “The efficacy and safety of qiliqiangxin according to baseline ejection fraction in patients with heart failure and reduced ejection fraction in QUEST.” European journal of heart failure (2026). PMID: 41771073 ↗

    L2RCTCited in: Definition, Classification, and Epidemiology, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Prognosis, Risk Stratification, and Palliative Care
  9. [9]

    Awashra A, Emara A, Amin AM et al.. “Beta-Blockers After Myocardial Infarction Without Reduced Ejection Fraction: A Meta-Analysis of Kaplan-Meier Reconstructed Individual Patient Data.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2026). PMID: 41714516 ↗

    L1SR_OBSCited in: Definition, Classification, and Epidemiology, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Pharmacological Management: The Four Pillars
  10. [10]

    Pastva AM, Reeves GR, Whellan DJ et al.. “Physical rehabilitation for older patients with acute HFpEF (REHAB-HFpEF) trial: Design and rationale.” American heart journal (2026). PMID: 41812966 ↗

    L5TRIAL_NONRANDOMCited in: Definition, Classification, and Epidemiology
  11. [11]

    Sideris K, Bunsawat K, Brinker L et al.. “The Effect of Vericiguat on Endothelial Function in Patients With Heart Failure With Reduced Ejection Fraction: A Pilot Randomized Study.” The American journal of cardiology (2026). PMID: 41765262 ↗

    L2RCTCited in: Definition, Classification, and Epidemiology, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Secondary and Emerging Pharmacotherapies, Acute Decompensated Heart Failure (ADHF) in HFrEF, Prognosis, Risk Stratification, and Palliative Care
  12. [12]

    Zhang L, Szili-Torok T, Lamont L et al.. “Pre- and post-diagnosis signalling lipid profiles in heart failure with preserved ejection fraction: a prospective cohort study.” EBioMedicine (2026). PMID: 41903475 ↗

    L2COHORTCited in: Definition, Classification, and Epidemiology
  13. [13]

    Özbek BT, Modin D, Sengeløv M et al.. “Left atrial strain and all-cause mortality in patients with heart failure with reduced ejection fraction: a retrospective cohort study.” BMJ open (2026). PMID: 41730559 ↗

    L3COHORTCited in: Definition, Classification, and Epidemiology, Etiology and Risk Factors, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Prognosis, Risk Stratification, and Palliative Care
  14. [14]

    Kozhevnikova MV, Emelianov AV, Zheleznykh EA et al.. “Impact of Digital Remote Monitoring on the Optimization of Guideline-Directed Medical Therapy Titration in Heart Failure With Reduced Ejection Fraction.” Kardiologiia (2026). PMID: 41925172 ↗

    L2RCTCited in: Definition, Classification, and Epidemiology, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Pharmacological Management: The Four Pillars, Acute Decompensated Heart Failure (ADHF) in HFrEF
  15. [15]

    Nowakowski M, Mazuruk M, Nogajski Ł et al.. “Epicardial adipose tissue as a determinant of heart failure prognosis: insights across ejection fraction phenotypes.” Cardiovascular diabetology (2026). PMID: 41803855 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification, and Epidemiology, Etiology and Risk Factors
  16. [16]

    Biegus J, Bayes-Genis A, von Haehling S et al.. “Contemporary heart failure evidence in 2025: a joint summary of key trials from the European Journal of Heart Failure and ESC Heart Failure Journal.” European journal of heart failure (2026). PMID: 41771104 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification, and Epidemiology
  17. [17]

    Imran TF, Kadivar N, Gillotti J et al.. “Translating Mechanistic Insights Into Action and Revealing New Pathways: Machine Learning Approaches in Heart Failure With Preserved Ejection Fraction.” Journal of the American Heart Association (2026). PMID: 41717938 ↗

    L5REVIEW_NARRATIVECited in: Definition, Classification, and Epidemiology
  18. [18]

    Khamboonruang S, Bunditboondee P, Jittham P et al.. “Comparative Cardiovascular Outcomes of SGLT2i Plus Low-Dose of Conventional Triple Therapy Versus High-Dose of Conventional Triple Therapy for Heart Failure with Reduced Ejection Fraction (HFrEF): A Retrospective Cohort Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 42075652 ↗

    L3COHORTCited in: Definition, Classification, and Epidemiology, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Pharmacological Management: The Four Pillars
  19. [19]

    Parizad R, Hatwal J, Taban Sadeghi M et al.. “Clinical Advances in Heart Failure with Preserved Ejection Fraction: A Systematic Review of Therapeutic and Mechanistic Evidence.” Vascular health and risk management (2026). PMID: 41953528 ↗

    L1SR_OBSCited in: Definition, Classification, and Epidemiology, Etiology and Risk Factors, Pharmacological Management: The Four Pillars
  20. [20]

    Han W, Jiao Y, Chen W et al.. “PRIME-HFrEF Trial: a randomized, double-blind, multi-dose umbilical cord-derived mesenchymal stem cell regimen for heart failure.” Signal transduction and targeted therapy (2026). PMID: 41888108 ↗

    L2RCTCited in: Definition, Classification, and Epidemiology, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation
  21. [21]

    Lam CSP, Bozkurt B, Cherney DZI et al.. “Kidney Disease and Heart Failure: Recent Advances and Current Challenges: Conclusions From a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.” JACC. Heart failure (2026). PMID: 41793402 ↗

    L1GUIDELINECited in: Etiology and Risk Factors, Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Pharmacological Management: The Four Pillars, Management of Comorbidities and Iron Deficiency
  22. [22]

    Huang D, Liang J, Zhou Y et al.. “Association of thyroid nodules with comorbidity burden and prognosis in patients with heart failure, anemia, and hyperuricemia: a retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 41890186 ↗

    L3COHORTCited in: Etiology and Risk Factors, Clinical Presentation and Diagnostic Evaluation, Prognosis, Risk Stratification, and Palliative Care
  23. [23]

    Pop-Busui R, Rasmussen S, Deanfield JE et al.. “Oral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.” JAMA internal medicine (2026). PMID: 41627802 ↗

    L1RCTCited in: Etiology and Risk Factors, Management of Comorbidities and Iron Deficiency, Prognosis, Risk Stratification, and Palliative Care
  24. [24]

    Pol T, Lindbäck J, Oldgren J et al.. “Plasma Biomarkers Associated With Heart Failure Hospitalization Among Patients With Atrial Fibrillation and Subtypes of Heart Failure.” Journal of the American Heart Association (2026). PMID: 41532553 ↗

    L2RCTCited in: Etiology and Risk Factors, Management of Comorbidities and Iron Deficiency, Prognosis, Risk Stratification, and Palliative Care
  25. [25]

    Madrini V, Souza PVR, Fernandes F et al.. “Sacubitril-Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: Primary Results of ANSWER-HF Randomized Trial.” Journal of the American College of Cardiology (2026). PMID: 41396086 ↗

    L1RCTCited in: Etiology and Risk Factors
  26. [26]

    Foà A, Vaduganathan M, Claggett BL et al.. “Finerenone-Related Risk of Hypotension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.” JACC. Heart failure (2026). PMID: 41364043 ↗

    L1RCTCited in: Etiology and Risk Factors, Pharmacological Management: The Four Pillars, Acute Decompensated Heart Failure (ADHF) in HFrEF
  27. [27]

    Lopes RD, Bocchi EA, Echeverría LE et al.. “Sacubitril/Valsartan vs Enalapril in Heart Failure Due to Chagas Disease: An Open-Label, Multicenter Randomized Clinical Trial.” JAMA (2026). PMID: 41335448 ↗

    L1RCTCited in: Etiology and Risk Factors, Pharmacological Management: The Four Pillars
  28. [28]

    Shetty VV, Patil LR, Patil SG et al.. “Exploring the mechanisms of yoga-based cardiac rehabilitation in heart failure via assessment of endothelial function, genomics and arterial health (Yoga-EndOmics): a study protocol.” BMJ open (2026). PMID: 41529878 ↗

    L5TRIAL_NONRANDOMCited in: Etiology and Risk Factors
  29. [29]

    Meyer P, Rocca A, Banus J et al.. “Study Protocol for HeartMagic: A Prospective Observational Cohort Characterizing Subtypes of Heart Failure With Preserved Ejection Fraction.” Journal of the American Heart Association (2025). PMID: 41378481 ↗

    L5TRIAL_NONRANDOMCited in: Etiology and Risk Factors
  30. [30]

    Tu KC, Weng YC, Liao CT et al.. “The effectiveness and safety of sacubitril/valsartan in real-world dialysis patients with heart failure reduced ejection fraction.” Medicine (2026). PMID: 41630233 ↗

    L2SR_OBSCited in: Etiology and Risk Factors, Pathophysiology and Neurohormonal Activation, Pharmacological Management: The Four Pillars, Management of Comorbidities and Iron Deficiency, Prognosis, Risk Stratification, and Palliative Care
  31. [31]

    Tana M, Piccinini R, Pinterpe G et al.. “Cardiotoxicity of Antitumor Agents: Therapeutic Challenges in Heart Failure with Reduced and Preserved Ejection Fraction.” International journal of molecular sciences (2026). PMID: 41977162 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors, Clinical Presentation and Diagnostic Evaluation
  32. [32]

    Antza C, Jordan J, McGowan B et al.. “Treating obesity and heart failure: a how-to-manage guide from the European Association for the Study of Obesity and the European Society of Hypertension working group on diabetes and metabolic risk factors.” Journal of hypertension (2026). PMID: 41818428 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors
  33. [33]

    Avogaro A. “Beyond glycemic control: How incretins are changing the cardiovascular trajectories of diabetes and obesity.” European journal of clinical investigation (2026). PMID: 41653035 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors
  34. [34]

    Evans MA, Walsh K. “The Immunological Consequences of Clonal Hematopoiesis in Heart Failure.” Immunological reviews (2026). PMID: 41546079 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors
  35. [35]

    Rodés-Cabau J, Mengi S, Salaun E et al.. “Transcatheter edge-to-edge repair in secondary mitral regurgitation.” EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology (2025). PMID: 41489737 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors
  36. [36]

    Russo E, Venturelli E, Leoncini G et al.. “Renal protection in heart failure with reduced ejection fraction: not all that glitters is gold.” European journal of internal medicine (2026). PMID: 41407587 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors, Acute Decompensated Heart Failure (ADHF) in HFrEF
  37. [37]

    Preda A, Tirandi A, Leo G et al.. “IL-6 in the spotlight: From cardiovascular pathophysiology to therapy.” European journal of clinical investigation (2026). PMID: 41340186 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors
  38. [38]

    Chaves VB, Barbosa LM, Oliveira VMR et al.. “VEXUS protocol as a prognostic tool in acute heart failure: A systematic review and Bayesian meta-analysis.” Current problems in cardiology (2026). PMID: 41747972 ↗

    L2SR_OBSCited in: Etiology and Risk Factors
  39. [39]

    Daidone M, Casuccio A, Soldano JS et al.. “Effects of intravenous furosemide plus small-volume hypertonic saline solutions on inflammatory, remodelling markers and epigenetics signatures of patients with congestive acute decompensated heart failure (ADHF).” Aging (2026). PMID: 41915883 ↗

    L1RCTCited in: Etiology and Risk Factors, Clinical Presentation and Diagnostic Evaluation, Acute Decompensated Heart Failure (ADHF) in HFrEF
  40. [40]

    Barghash MH. “Sex-Based Differences in Advanced Heart Failure.” Heart failure clinics (2026). PMID: 41895895 ↗

    L5REVIEW_NARRATIVECited in: Etiology and Risk Factors, Advanced Heart Failure: LVAD and Transplantation
  41. [41]

    Fudim M, Kovacevic-Preradovic T, Zdravkovic M et al.. “Association between functional Status and cardiac function in chronic heart failure: insights from the C-MIC II Trial.” ESC heart failure (2026). PMID: 41941602 ↗

    L1RCTCited in: Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation
  42. [42]

    Buswell V, Massie E, Tessitore E et al.. “Impact of the Cardio-Meds Mobile App on Heart Failure Knowledge and Medication Adherence: Pilot Randomized Controlled Trial.” JMIR cardio (2026). PMID: 41730174 ↗

    L1RCTCited in: Pathophysiology and Neurohormonal Activation
  43. [43]

    Savarese G, Basile C, Mebazaa A et al.. “Ten years real-world experience with sacubitril/valsartan in patients with heart failure with reduced ejection fraction.” ESC heart failure (2026). PMID: 41920861 ↗

    L2SR_OBSCited in: Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Prognosis, Risk Stratification, and Palliative Care
  44. [44]

    Irlik K, Piaśnik J, Hendel M et al.. “Mortality and heart failure hospitalizations in heart failure with preserved ejection fraction compared to heart failure with reduced ejection fraction: a systematic review and meta-analysis.” ESC heart failure (2026). PMID: 41711724 ↗

    L2SR_OBSCited in: Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation
  45. [45]

    Dandamudi M, Ho VQT, Samaniego-Laguna MA et al.. “Cimlanod, a Second-Generation Nitroxyl Donor, in Heart Failure with Reduced Ejection Fraction: A Meta-Analysis of Hemodynamic Efficacy and Safety Profile.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2026). PMID: 41686423 ↗

    L1SR_OBSCited in: Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Acute Decompensated Heart Failure (ADHF) in HFrEF
  46. [46]

    Kotte M, Sibhai I, Shaikh Z et al.. “Conduction System Pacing Versus Biventricular Cardiac Resynchronization in HFmrEF: A Systematic Review and Meta-Analysis.” Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc (2026). PMID: 41902448 ↗

    L2SR_OBSCited in: Pathophysiology and Neurohormonal Activation, Clinical Presentation and Diagnostic Evaluation, Device Therapy: ICD and CRT, Prognosis, Risk Stratification, and Palliative Care
  47. [47]

    Siddiqui HA, Kotte M, Omar HS et al.. “Outcomes of Left Bundle Branch Area Pacing in Heart Failure Patients: A Systematic Review.” Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc (2026). PMID: 41630541 ↗

    L2SR_OBSCited in: Pathophysiology and Neurohormonal Activation, Device Therapy: ICD and CRT, Prognosis, Risk Stratification, and Palliative Care
  48. [48]

    Occhino G, Musa A, Andreano A et al.. “Prognostic models in populations with heart failure: a systematic review and meta-analysis.” Systematic reviews (2026). PMID: 41715180 ↗

    L2SR_OBSCited in: Clinical Presentation and Diagnostic Evaluation, Prognosis, Risk Stratification, and Palliative Care
  49. [49]

    Guo J, Miao R, Fan Q et al.. “Yangxinshi Tablet protects against post-myocardial infarction heart failure with reduced ejection fraction by improving energy metabolism through inhibition of FOXO1/PDK4 signaling.” Chinese journal of natural medicines (2026). PMID: 42062031 ↗

    L5OTHERCited in: Clinical Presentation and Diagnostic Evaluation
  50. [50]

    Miyoshi Y, Kato T, Morimoto T et al.. “Restrictive filling pattern of transmitral inflow in acute decompensated heart failure with preserved ejection fraction: insights from the KCHF registry.” Open heart (2026). PMID: 41997617 ↗

    L3OTHERCited in: Clinical Presentation and Diagnostic Evaluation, Acute Decompensated Heart Failure (ADHF) in HFrEF
  51. [51]

    Schwegel N, Höller V, Santner V et al.. “Prognostic value of circulating glypican-4 in chronic heart failure.” Journal of molecular medicine (Berlin, Germany) (2026). PMID: 41944882 ↗

    L2OTHERCited in: Clinical Presentation and Diagnostic Evaluation
  52. [52]

    Chaudhari M, Makhloufi J, Doelling B et al.. “Structural and Metabolic Remodeling of Skeletal Muscle in Heart Failure with Reduced Ejection Fraction: A Review: Beyond the Failing Heart.” International journal of molecular sciences (2026). PMID: 41898746 ↗

    L5REVIEW_NARRATIVECited in: Clinical Presentation and Diagnostic Evaluation
  53. [53]

    Khan MN, Soomro NA, Iqbal MN et al.. “Quality of Life Assessment in Heart Failure Patients: Insights from a Low- to Middle-Income Country.” Global heart (2026). PMID: 41867907 ↗

    L2OTHERCited in: Clinical Presentation and Diagnostic Evaluation
  54. [54]

    Satoh T, Sugimura K, Fukumoto Y et al.. “Prognostic Impact of Elevated Pulmonary Vascular Resistance in Group 2 Pulmonary Hypertension: Insights From a Japanese Multicenter Registry.” Journal of the American Heart Association (2026). PMID: 41859897 ↗

    L2OTHERCited in: Clinical Presentation and Diagnostic Evaluation
  55. [55]

    Johansson JSM, Henrysson J, Basic C et al.. “Biomarkers of iron deficiency and prognosis in patients hospitalised with new-onset heart failure and a reduced left ventricular ejection fraction.” Open heart (2026). PMID: 41856675 ↗

    L3OTHERCited in: Clinical Presentation and Diagnostic Evaluation
  56. [56]

    Dattilo G, Licordari R, Imbalzano E et al.. “Long-term outcomes following sacubitril/valsartan therapy for chronic HFrEF: an Italian real-world multicentre study.” ESC heart failure (2026). PMID: 41843757 ↗

    L3OTHERCited in: Clinical Presentation and Diagnostic Evaluation
  57. [57]

    Bruno J, Daghmouri A, Sadoune M et al.. “Cardiac biomarkers response under angiotensin receptor-neprilysin inhibitor: a sub-analysis of the NATRIUM-HF study.” ESC heart failure (2026). PMID: 41834516 ↗

    L2OTHERCited in: Clinical Presentation and Diagnostic Evaluation, Pharmacological Management: The Four Pillars, Acute Decompensated Heart Failure (ADHF) in HFrEF
  58. [58]

    Zuin M, Temporelli P, Bilato C et al.. “Robustness of randomized controlled trial evidence for SGLT2 inhibitors in heart failure with preserved and mildly reduced ejection fraction.” European journal of internal medicine (2026). PMID: 41314931 ↗

    L1SR_MA_RCTCited in: Pharmacological Management: The Four Pillars
  59. [59]

    Ferreira JP, Packer M, Butler J et al.. “Serum Magnesium, Outcomes, and the Effect of Empagliflozin in Heart Failure With Mildly Reduced and Preserved Ejection Fraction: Findings From EMPEROR-Preserved.” JACC. Heart failure (2026). PMID: 41493412 ↗

    L1RCTCited in: Pharmacological Management: The Four Pillars, Acute Decompensated Heart Failure (ADHF) in HFrEF, Landmark Trials and Key Evidence, Prognosis, Risk Stratification, and Palliative Care
  60. [60]

    Ferreira JP, Anker SD, Butler J et al.. “Serum Magnesium and the Effect of Empagliflozin in Heart Failure With Reduced Ejection Fraction: Findings From EMPEROR-Reduced.” JACC. Heart failure (2026). PMID: 41171249 ↗

    L1RCTCited in: Pharmacological Management: The Four Pillars, Landmark Trials and Key Evidence
  61. [61]

    Myte R, Mattsson A, Poole M et al.. “Survival Odds to Minimize Risk Heterogeneity Bias in Heart Failure Trials: Application to Dapagliflozin.” Circulation. Heart failure (2025). PMID: 41170566 ↗

    L1RCTCited in: Pharmacological Management: The Four Pillars, Landmark Trials and Key Evidence
  62. [62]

    Ferreira JP, Vaduganathan M, Claggett BL et al.. “Interplay of serum potassium and kidney function with finerenone in heart failure with mildly reduced or preserved ejection fraction: Findings from FINEARTS-HF.” European journal of heart failure (2025). PMID: 41039732 ↗

    L1RCTCited in: Pharmacological Management: The Four Pillars, Acute Decompensated Heart Failure (ADHF) in HFrEF
  63. [63]

    Semenycheva I, Larina S, Zakharova L et al.. “Safety of Repeated Levosimendan Use in Chronic Heart Failure.” Journal of cardiovascular pharmacology (2026). PMID: 41568919 ↗

    L1RCTCited in: Pharmacological Management: The Four Pillars, Acute Decompensated Heart Failure (ADHF) in HFrEF, Prognosis, Risk Stratification, and Palliative Care
  64. [64]

    Jiang N, Zhang Y, Tang Y et al.. “Comparative efficacy and safety of different SGLT2 inhibitor-based combination strategies in HFrEF: a systematic review and network meta-analysis.” Frontiers in endocrinology (2025). PMID: 41550872 ↗

    L1SR_OBSCited in: Pharmacological Management: The Four Pillars, Prognosis, Risk Stratification, and Palliative Care
  65. [65]

    Suzuki K, Osa S, Takeshita S et al.. “Additive Effects of Angiotensin Receptor-Neprilysin Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Neurohormonal Inhibition Therapy in Severe HFrEF: A Systematic Review and Network Meta-analysis.” American journal of cardiovascular drugs : drugs, devices, and other interventions (2026). PMID: 41549334 ↗

    L1SR_OBSCited in: Pharmacological Management: The Four Pillars
  66. [66]

    Bhandari K, Qadri M, Dhakal R et al.. “The Impact of SGLT2 Inhibitors on Pulmonary Artery Pressures and Pulmonary Hemodynamics in Patients With Heart Failure: A Systematic Review.” Cardiovascular therapeutics (2025). PMID: 41164749 ↗

    L2SR_OBSCited in: Pharmacological Management: The Four Pillars
  67. [67]

    Barbosa AV, Araújo Silva LC, Rotta I et al.. “Does Sex Affect the Efficacy, Safety, and Quality of Life Outcomes for Patients Using Angiotensin Receptor Neprilysin Inhibitor, Soluble Guanylate Cyclase Stimulators, and Cardiac Myosin Activators in Heart Failure? A Systematic Review.” Heart, lung & circulation (2025). PMID: 41062399 ↗

    L1SR_OBSCited in: Pharmacological Management: The Four Pillars
  68. [68]

    Senanayake S, Lee ASY, Graves N et al.. “Treatment gaps in guideline-directed medical therapy for HFrEF in Singapore: findings from a multicentre retrospective cohort study.” BMJ open (2026). PMID: 41819588 ↗

    L3COHORTCited in: Pharmacological Management: The Four Pillars, Management of Comorbidities and Iron Deficiency, Acute Decompensated Heart Failure (ADHF) in HFrEF
  69. [69]

    Li JJ, Parajuli DR, Brown J et al.. “Maximum tolerated medication dose and other predictors of mortality in heart failure with reduced ejection fraction: retrospective cohort study.” BMC cardiovascular disorders (2025). PMID: 41146052 ↗

    L3COHORTCited in: Pharmacological Management: The Four Pillars
  70. [70]

    Albalushi MA, Neshat-Mokadem L, Al-Mawaali G. “Evaluation of prescribing adherence to guideline-directed medical therapy in patients with chronic heart failure: a retrospective study at the National Heart Centre in Oman.” BMC cardiovascular disorders (2025). PMID: 41136931 ↗

    L3COHORTCited in: Pharmacological Management: The Four Pillars
  71. [71]

    Greene SJ, Adam A, Schmedt N et al.. “Contemporary Guideline-Directed Medical Therapy for Heart Failure in the United States: The EMPACE Study.” Journal of the American Heart Association (2026). PMID: 41804888 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars, Acute Decompensated Heart Failure (ADHF) in HFrEF
  72. [72]

    Kobayashi M, Monzo L, Baudry G et al.. “Real-world data on early initiation of sodium-glucose co-transporter-2 inhibitors in newly diagnosed heart failure with reduced ejection fraction.” ESC heart failure (2026). PMID: 41711250 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars
  73. [73]

    Oliva F, Orso F, Colivicchi F et al.. “Medical treatments at 6 months in hospitalized and ambulatory HFrEF patients in the BRING-UP 3 Heart Failure study.” ESC heart failure (2026). PMID: 41711238 ↗

    L2OTHERCited in: Pharmacological Management: The Four Pillars, Acute Decompensated Heart Failure (ADHF) in HFrEF
  74. [74]

    Sauer AJ, Ter Maaten JM, Savarese G. “Established and emerging pharmacologic options and unmet needs in HFpEF and HFmrEF.” ESC heart failure (2026). PMID: 41711220 ↗

    L5REVIEW_NARRATIVECited in: Pharmacological Management: The Four Pillars, Management of Comorbidities and Iron Deficiency, Acute Decompensated Heart Failure (ADHF) in HFrEF
  75. [75]

    Erzeel J, van Es M, Mullens W et al.. “Evolving Mineralocorticoid Receptor Antagonism: a Narrative Review on Differences between Steroidal MRAs, Non-Steroidal MRAs and Aldosterone Synthase Inhibitors in Cardiorenal Disease.” Current heart failure reports (2026). PMID: 41615644 ↗

    L5REVIEW_NARRATIVECited in: Pharmacological Management: The Four Pillars, Management of Comorbidities and Iron Deficiency, Acute Decompensated Heart Failure (ADHF) in HFrEF
  76. [76]

    Greene SJ, Xu H, Chiswell K et al.. “One-Year Outcomes in Patients Hospitalized for Heart Failure With Reduced Ejection Fraction Prescribed Quadruple Medical Therapy at Discharge.” JAMA cardiology (2026). PMID: 41604197 ↗

    L3OTHERCited in: Pharmacological Management: The Four Pillars, Acute Decompensated Heart Failure (ADHF) in HFrEF
  77. [77]

    Ali MS, Greer KM, Ganai S et al.. “Association of an Algorithm-Generated Medication Optimization Score With Clinical Outcomes in Ambulatory Patients With Heart Failure.” Pharmacotherapy (2026). PMID: 41548207 ↗

    L3OTHERCited in: Pharmacological Management: The Four Pillars
  78. [78]

    Mentz RJ, Butler J, McMullan CJ et al.. “Blood pressure, safety and clinical efficacy of vericiguat in chronic heart failure with reduced ejection fraction: Insights from the VICTOR trial.” European journal of heart failure (2025). PMID: 41020754 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies
  79. [79]

    Westerhout CM, Alemayehu W, Cohen-Solal A et al.. “Geographic region variation in patient characteristics, clinical outcomes and treatment of HFrEF in the VICTORIA trial.” ESC heart failure (2025). PMID: 40977249 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies
  80. [80]

    Butler J, McMullan CJ, Anstrom KJ et al.. “Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.” Lancet (London, England) (2025). PMID: 40897189 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies, Acute Decompensated Heart Failure (ADHF) in HFrEF
  81. [81]

    Zannad F, O'Connor CM, Butler J et al.. “Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.” Lancet (London, England) (2025). PMID: 40897188 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies, Acute Decompensated Heart Failure (ADHF) in HFrEF
  82. [82]

    Zannad F, Reddy YNV, Barash I et al.. “Effect of Vericiguat on Total Heart Failure Events in Compensated Outpatients With HFrEF: Insights From VICTOR.” Journal of the American College of Cardiology (2025). PMID: 40892609 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies, Acute Decompensated Heart Failure (ADHF) in HFrEF
  83. [83]

    Butler J, Fioretti F, McMullan CJ et al.. “Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.” European heart journal (2026). PMID: 40884032 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies
  84. [84]

    Bavendiek U, Thomas NH, Berliner D et al.. “DIGitoxin to Improve ouTcomes in patients with advanced chronic Heart Failure (DIGIT-HF): Baseline characteristics compared to recent randomized controlled heart failure trials.” European journal of heart failure (2025). PMID: 40389288 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies
  85. [85]

    Saldarriaga CI, Zannad F, McMullan CJ et al.. “Baseline characteristics of contemporary trial participants with heart failure and reduced ejection fraction: The VICTOR trial.” European journal of heart failure (2025). PMID: 39956649 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies
  86. [86]

    Reddy YNV, Butler J, Anstrom KJ et al.. “Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial.” European journal of heart failure (2025). PMID: 39473305 ↗

    L5RCTCited in: Secondary and Emerging Pharmacotherapies
  87. [87]

    Kittipibul V, Mentz RJ, Young R et al.. “Projecting the benefit of vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA trial.” ESC heart failure (2025). PMID: 39434631 ↗

    L2RCTCited in: Secondary and Emerging Pharmacotherapies, Landmark Trials and Key Evidence
  88. [88]

    Westerhout CM, Rathwell S, Anstrom KJ et al.. “Comparing Analytical Methods for Composite End Points in Clinical Trials: Insights from the Vericiguat Global Study in Subjects with Heart Failure With Reduced Ejection Fraction Trial.” Journal of cardiac failure (2025). PMID: 39182825 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies
  89. [89]

    Tromp J, Lam CSP, Alemayehu W et al.. “Biomarker profiles associated with reverse ventricular remodelling in patients with heart failure and a reduced ejection fraction: Insights from the echocardiographic substudy of the VICTORIA trial.” European journal of heart failure (2024). PMID: 39078607 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies
  90. [90]

    Khan MS, Butler J, Young R et al.. “Vericiguat and Cardiovascular Outcomes in Heart Failure by Baseline Diabetes Status: Insights From the VICTORIA Trial.” JACC. Heart failure (2024). PMID: 38934967 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies
  91. [91]

    Ezekowitz J, Alemayehu W, Edelmann F et al.. “Diuretic use and outcomes in patients with heart failure with reduced ejection fraction: Insights from the VICTORIA trial.” European journal of heart failure (2024). PMID: 38450878 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies
  92. [92]

    Mentz RJ, Stebbins A, Butler J et al.. “Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection Fraction.” JACC. Heart failure (2024). PMID: 38363272 ↗

    L1RCTCited in: Secondary and Emerging Pharmacotherapies
  93. [93]

    Tang H, Germinal K, Milfort A et al.. “The most effective combination of pharmacological therapy for heart failure with reduced ejection fraction: a network meta-analysis of randomized controlled trials.” BMC cardiovascular disorders (2024). PMID: 39578732 ↗

    L1SR_MA_RCTCited in: Secondary and Emerging Pharmacotherapies
  94. [94]

    Waranugraha Y, Rizal A, Tjahjono CT et al.. “A Systematic Review and Meta-Analysis of Randomised Controlled Trials Assessing Clinical and Haemodynamic Outcomes of Ivabradine in Heart Failure With Reduced Ejection Fraction Patients.” Heart, lung & circulation (2024). PMID: 38729854 ↗

    L1SR_MA_RCTCited in: Secondary and Emerging Pharmacotherapies
  95. [95]

    Margaryan R, Sepehrvand N, Ouwerkerk W et al.. “Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction.” Circulation. Heart failure (2025). PMID: 40910162 ↗

    L1SR_OBSCited in: Secondary and Emerging Pharmacotherapies
  96. [96]

    van Essen BJ, Ceelen DCH, Ouwerkerk W et al.. “Pharmacologic Treatment of Heart Failure With Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.” Journal of the American College of Cardiology (2025). PMID: 40892608 ↗

    L1SR_OBSCited in: Secondary and Emerging Pharmacotherapies, Acute Decompensated Heart Failure (ADHF) in HFrEF
  97. [97]

    Butt JH, Doi SN, Thune JJ et al.. “Long-Term Effect of ICDs in Nonischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up Analysis of DANISH.” Journal of the American College of Cardiology (2025). PMID: 41123523 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  98. [98]

    Doi SN, Yafasova A, Thune JJ et al.. “Atrial fibrillation and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: insights from the DANISH trial.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2025). PMID: 40990042 ↗

    L1RCTCited in: Device Therapy: ICD and CRT, Management of Comorbidities and Iron Deficiency
  99. [99]

    Gouda P, Alemayehu W, Voors AA et al.. “Implantable cardioverter-defibrillators in ischaemic versus non-ischaemic heart failure: Insights from the VICTORIA trial.” European journal of heart failure (2025). PMID: 40539883 ↗

    L2RCTCited in: Device Therapy: ICD and CRT
  100. [100]

    Merkel E, Hatala R, Szigeti M et al.. “Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes.” JACC. Heart failure (2025). PMID: 39614838 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  101. [101]

    Leonardo C, Ermenegildo R, Christof K et al.. “Multipoint pacing is associated with improved prognosis and cardiac resynchronization therapy response: MORE-CRT MPP randomized study secondary analyses.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2024). PMID: 39365705 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  102. [102]

    Merkely B, Hatala R, Merkel E et al.. “Benefits of upgrading right ventricular to biventricular pacing in heart failure patients with atrial fibrillation.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2024). PMID: 38979560 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  103. [103]

    Cha YM, Lee HC, Mulpuru SK et al.. “Cardiac resynchronization therapy for patients with mild to moderately reduced ejection fraction and left bundle branch block.” Heart rhythm (2024). PMID: 38772431 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  104. [104]

    Yafasova A, Doi SN, Thune JJ et al.. “Effect of Implantable Cardioverter-defibrillators in Nonischemic Heart Failure According to Background Medical Therapy: Extended Follow-up of the DANISH Trial.” Journal of cardiac failure (2024). PMID: 38750689 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  105. [105]

    Karacan MN, Doi SN, Yafasova A et al.. “New York Heart Association functional class and implantable cardioverter-defibrillator in non-ischaemic heart failure with reduced ejection fraction: Extended follow-up of the DANISH trial.” European journal of heart failure (2024). PMID: 38733253 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  106. [106]

    Butt JH, Bundgaard JS, Schou M et al.. “Implantable Cardioverter-Defibrillator and Frailty in Non-ischemic Heart Failure With Reduced Ejection Fraction: Extended Follow-Up of the DANISH Trial.” The American journal of cardiology (2026). PMID: 40998196 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  107. [107]

    Pung X, Chua JJL, Fong KY et al.. “Conduction System Pacing Versus Biventricular Cardiac Resynchronization Pacing: Meta-Analysis on Outcomes in Patients with Non-Left Bundle Branch Block.” Medicina (Kaunas, Lithuania) (2025). PMID: 40731870 ↗

    L2SR_OBSCited in: Device Therapy: ICD and CRT
  108. [108]

    Kolokathis K, Doundoulakis I, Tsiachris D et al.. “Efficacy and safety of leadless cardiac resynchronization therapy: An updated meta-analysis.” Journal of cardiology (2025). PMID: 40118339 ↗

    L2SR_OBSCited in: Device Therapy: ICD and CRT
  109. [109]

    Goldenberg I, Zareba W, Ezekowitz JA et al.. “Rationale and design of the comparative effectiveness of ICD vs non-ICD therapy in contemporary heart failure patients at a low risk for arrhythmic death (CONTEMP-ICD) trial.” American heart journal (2026). PMID: 40914445 ↗

    L5TRIAL_NONRANDOMCited in: Device Therapy: ICD and CRT
  110. [110]

    Zimerman A, Dal Forno A, Rohde LE et al.. “Conduction system pacing vs biventricular resynchronization in heart failure with reduced ejection fraction and left bundle branch block: Rationale and design of the PhysioSync-HF Trial.” American heart journal (2025). PMID: 40473010 ↗

    L5TRIAL_NONRANDOMCited in: Device Therapy: ICD and CRT
  111. [111]

    Fudim M, Khan MS, Linz D et al.. “Safety and tolerability of the M2 muscarinic acetylcholine receptor modulator BAY 2413555 in heart failure with reduced ejection fraction in the REMOTE-HF study.” Scientific reports (2024). PMID: 39738130 ↗

    L1RCTCited in: Device Therapy: ICD and CRT
  112. [112]

    Decker SRR, Etges APBDS, Zimerman A et al.. “Conduction System Pacing vs Biventricular Pacing in Chronic Heart Failure: Protocol for the Economic Analysis of the PhysioSync-HF Trial.” Arquivos brasileiros de cardiologia (2025). PMID: 41779515 ↗

    L5TRIAL_NONRANDOMCited in: Device Therapy: ICD and CRT
  113. [113]

    Gupta AR, Kumar A, Cao JJL et al.. “Preimplantation AI-ECG Age as a Predictor of Survival Following Cardiac Resynchronization Therapy.” JACC. Clinical electrophysiology (2026). PMID: 41441802 ↗

    L3OTHERCited in: Device Therapy: ICD and CRT
  114. [114]

    Burri H, Leclercq C, Behar N et al.. “Controversy: in heart failure patients with a reduced ejection fraction and left bundle branch block, conduction system pacing can be a valid alternative to biventricular pacing-pro and contra.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2025). PMID: 41433135 ↗

    L5REVIEW_NARRATIVECited in: Device Therapy: ICD and CRT
  115. [115]

    Nakamura T, Ishibashi K, Ueda N et al.. “Left Ventricular Ejection Fraction Improvement and Ventricular Arrhythmia Risk in Patients With Heart Failure.” Circulation journal : official journal of the Japanese Circulation Society (2026). PMID: 41371693 ↗

    L3OTHERCited in: Device Therapy: ICD and CRT
  116. [116]

    Yeo YH, Ong TE, Vignarajah A et al.. “Propensity-Matched Five-Year Cardiac Resynchronization Therapy Outcomes in Sarcoidosis With Heart Failure.” Journal of cardiovascular electrophysiology (2026). PMID: 41286588 ↗

    L3OTHERCited in: Device Therapy: ICD and CRT
  117. [117]

    Laborante R, Valente V, Benson L et al.. “Associations between cardiac resynchronization therapy and clinical outcomes according to the atrial fibrillation status in patients with heart failure with reduced ejection fraction.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2025). PMID: 41253706 ↗

    L2OTHERCited in: Device Therapy: ICD and CRT
  118. [118]

    Ferreira DR, Cazeiro DI, Brito J et al.. “Impact of early intensive GDMT on LVEF recovery and ICD decision making in de novo HFrEF.” ESC heart failure (2025). PMID: 41206800 ↗

    L2OTHERCited in: Device Therapy: ICD and CRT
  119. [119]

    Ravikulan R, Chavali S, Gunton JE et al.. “Glucagon-like peptide-1 receptor agonists reduce atrial fibrillation among patients with heart failure with preserved and mildly reduced ejection fraction - a meta-analysis of randomized controlled trials.” European journal of heart failure (2025). PMID: 41216984 ↗

    L1SR_MA_RCTCited in: Management of Comorbidities and Iron Deficiency
  120. [120]

    Böhm M, Butler J, Abdin A et al.. “Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-Reduced.” European journal of heart failure (2025). PMID: 40956156 ↗

    L1RCTCited in: Management of Comorbidities and Iron Deficiency, Landmark Trials and Key Evidence
  121. [121]

    Redline S, Li D, Javaheri S et al.. “Nocturnal Oxygen Therapy for Central Sleep Apnea in Patients with Heart Failure: A Multisite, Double-Blind, Sham-controlled Randomized Clinical Trial (LOFT-HF).” Annals of the American Thoracic Society (2025). PMID: 40929650 ↗

    L1RCTCited in: Management of Comorbidities and Iron Deficiency
  122. [122]

    Song Z, Wang SY, Qidong Z et al.. “Catheter ablation versus medical rate control for persistent atrial fibrillation in older heart failure patients with reduced ejection fraction.” Heart (British Cardiac Society) (2025). PMID: 40393692 ↗

    L1RCTCited in: Management of Comorbidities and Iron Deficiency
  123. [123]

    Yatsu S, Woo A, Horvath CM et al.. “LV Structure and Function in HFrEF With and Without Peak-Flow-Triggered Adaptive Servo-Ventilation-Treated Sleep-Disordered Breathing.” JACC. Heart failure (2026). PMID: 40310326 ↗

    L1RCTCited in: Management of Comorbidities and Iron Deficiency
  124. [124]

    Martens P, Augusto SN, Erzeel J et al.. “Effects of Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction: Insights From CABANA.” JACC. Heart failure (2025). PMID: 40243977 ↗

    L1RCTCited in: Management of Comorbidities and Iron Deficiency
  125. [125]

    Palcău CA, Păduraru LF, Paraschiv C et al.. “Renal Biomarkers and Prognosis in HFpEF and HFrEF: The Role of Albuminuria and eGFR-A Systematic Review.” Medicina (Kaunas, Lithuania) (2025). PMID: 40870431 ↗

    L2SR_OBSCited in: Management of Comorbidities and Iron Deficiency
  126. [126]

    Joshi M, Tran P, Barber TM et al.. “Arterial stiffness in acute decompensated heart failure and acute kidney injury: a prospective observational cohort study protocol in a tertiary hospital setting.” BMJ open (2025). PMID: 40550719 ↗

    L5TRIAL_NONRANDOMCited in: Management of Comorbidities and Iron Deficiency
  127. [127]

    Tang X, He R, Zhang P. “Association between ultra-short-term heart rate variability and atrial fibrillation in heart failure population: a protocol for a prospective observational cohort study.” BMJ open (2025). PMID: 40750283 ↗

    L5COHORTCited in: Management of Comorbidities and Iron Deficiency
  128. [128]

    Boehmer AA, Ninni S, Heijman J et al.. “The clinical pathophysiology of atrial fibrillation: outstanding questions from bedside to bench and back.” Physiological reviews (2026). PMID: 41543444 ↗

    L5REVIEW_NARRATIVECited in: Management of Comorbidities and Iron Deficiency
  129. [129]

    Irving C, Azeka E, Adorisio R et al.. “The International Society for Heart and Lung Transplantation Guidelines for the Management of Pediatric Heart Failure (Update From 2014).” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2025). PMID: 40838915 ↗

    L1GUIDELINECited in: Advanced Heart Failure: LVAD and Transplantation
  130. [130]

    Rorris FP, Antonopoulos CN, Kyriakopoulos CP et al.. “Implantable cardioverter defibrillators in left ventricular assist device patients: Α systematic review and meta-analysis.” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2021). PMID: 34176727 ↗

    L1SR_OBSCited in: Advanced Heart Failure: LVAD and Transplantation
  131. [131]

    Mann DL, Greene SJ, Givertz MM et al.. “Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial.” JACC. Heart failure (2020). PMID: 32641226 ↗

    L5TRIAL_NONRANDOMCited in: Advanced Heart Failure: LVAD and Transplantation
  132. [132]

    Hitzeroth J, Mpe M, Klug E et al.. “2020 Heart Failure Society of South Africa perspective on the 2016 European Society of Cardiology Chronic Heart Failure Guidelines.” South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde (2020). PMID: 32880257 ↗

    L1GUIDELINECited in: Advanced Heart Failure: LVAD and Transplantation
  133. [133]

    Gravino R, Falco L, Amarelli C et al.. “Management of arrhythmias in left ventricular assist device recipients.” Heart failure reviews (2025). PMID: 41307738 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  134. [134]

    Barkoudah E, Yancy CW. “Heart Failure with Reduced Ejection Fraction.” The Medical clinics of North America (2025). PMID: 41136059 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  135. [135]

    Wattanachayakul P, Kittipibul V, Abraham WT et al.. “Phenotype-guided approach for device-based therapies in heart failure.” Heart failure reviews (2025). PMID: 41028654 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  136. [136]

    Miyamoto SD, Irving C, Azeka E et al.. “Authors Insights on the Updated International Society for Heart and Lung Transplantation Guidelines for the Management of Pediatric Heart Failure (Update From 2014).” The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation (2025). PMID: 40947169 ↗

    L1REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  137. [137]

    Kim R, Kittipibul V, Bhatt S et al.. “Device-based therapies for heart failure with preserved ejection fraction.” Heart failure reviews (2025). PMID: 40180634 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  138. [138]

    Ilonze OJ, Ebong IA, Guglin M et al.. “Considerations in the Diagnosis and Management of Pulmonary Hypertension Associated With Left Heart Disease.” JACC. Heart failure (2024). PMID: 38970588 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  139. [139]

    Srivastava PK, Kittleson MM. “Modern advances in heart transplantation.” Progress in cardiovascular diseases (2024). PMID: 38244826 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  140. [140]

    Soni B, Gopinathannair R. “Managing ventricular arrhythmias and implantable cardiac defibrillator shocks after left ventricular assist device implantation.” Journal of cardiovascular electrophysiology (2024). PMID: 38013210 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  141. [141]

    Eisen HJ, Flack JM, Atluri P et al.. “Management of Hypertension in Patients With Ventricular Assist Devices: A Scientific Statement From the American Heart Association.” Circulation. Heart failure (2022). PMID: 35430896 ↗

    L1REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  142. [142]

    Mwansa H, Lewsey S, Mazimba S et al.. “Racial/Ethnic and Gender Disparities in Heart Failure with Reduced Ejection Fraction.” Current heart failure reports (2021). PMID: 33666856 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  143. [143]

    DeFilippis EM, Guazzi M, Colombo PC et al.. “A right ventricular state of mind in the progression of heart failure with reduced ejection fraction: implications for left ventricular assist device therapy.” Heart failure reviews (2021). PMID: 32162141 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  144. [144]

    Jin C, Hsu J, Frenkel D et al.. “Unique technique to relieve left ventricular assist device electromagnetic interference with an implantable cardioverter defibrillator.” Journal of cardiovascular electrophysiology (2021). PMID: 33345375 ↗

    L4CASE_REPORTCited in: Advanced Heart Failure: LVAD and Transplantation
  145. [145]

    Sreedhara K, Panjrath G. “Patient Selection, Referral Timing, and Advanced Heart Disease Therapy Options for Heart Failure with Reduced Ejection Fraction.” Heart failure clinics (2026). PMID: 41895891 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  146. [146]

    Kittleson MM. “Who is the Candidate? The Heart Transplant Evaluation Process.” Methodist DeBakey cardiovascular journal (2025). PMID: 40384741 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  147. [147]

    Bitar A, Aaronson K. “When all Else Fails, Try This: The HeartMate III Left Ventricle Assist Device.” Heart failure clinics (2024). PMID: 39216930 ↗

    L5REVIEW_NARRATIVECited in: Advanced Heart Failure: LVAD and Transplantation
  148. [148]

    Samaniego-Laguna MA, Tripoli A, Gamarra-Valverde NN et al.. “Efficacy of cardiac myosin activators compared to placebo in patients with heart failure and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials.” Heart & lung : the journal of critical care (2026). PMID: 41145106 ↗

    L1SR_MA_RCTCited in: Acute Decompensated Heart Failure (ADHF) in HFrEF
  149. [149]

    Wu J, Pei Y, Wu J et al.. “Efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a meta-analysis of randomized controlled trials.” BMC cardiovascular disorders (2025). PMID: 41023853 ↗

    L1SR_MA_RCTCited in: Acute Decompensated Heart Failure (ADHF) in HFrEF
  150. [150]

    Chang HY, Liao CT, Heidenreich PA et al.. “Implementation of the Get With The Guidelines-Heart Failure Adherence to Science, Implementation in Asia (GWTG-HF A.S.I.A.) Program in Taiwan.” Journal of the American Heart Association (2026). PMID: 41413759 ↗

    L2OTHERCited in: Acute Decompensated Heart Failure (ADHF) in HFrEF
  151. [151]

    Berg DD, Docherty KF, Talebi A et al.. “Growth Differentiation Factor-15 and the Effect of Dapagliflozin in Heart Failure: Insights From the DAPA-HF Trial.” Journal of cardiac failure (2026). PMID: 40819681 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  152. [152]

    McDowell K, Welsh P, Docherty KF et al.. “Cellular Adhesion Molecules and Adverse Outcomes in Chronic Heart Failure: Findings From the DAPA-HF Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 40465275 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  153. [153]

    Shaddy R, Gong J, Garito T et al.. “Association between NT-proBNP changes and clinical outcomes in paediatric patients with heart failure: Insights from PANORAMA-HF and PARADIGM-HF.” ESC heart failure (2025). PMID: 40353367 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  154. [154]

    Chimura M, Butt JH, Matsumoto S et al.. “Comprehensive Analysis of the Effects of Sacubitril/Valsartan According to Sex Among Patients With Heart Failure and Reduced Ejection Fraction in PARADIGM-HF.” Journal of the American Heart Association (2025). PMID: 40265590 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  155. [155]

    Docherty KF, McDowell K, Welsh P et al.. “Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin: An Exploratory Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.” JACC. Heart failure (2025). PMID: 40088234 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  156. [156]

    Gupta SD, Butt JH, McMurray EGM et al.. “Effects of sacubitril/valsartan according to background beta-blocker therapy in patients with heart failure and reduced ejection fraction: Insights from PARADIGM-HF.” European journal of heart failure (2025). PMID: 39563094 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  157. [157]

    Matsumoto S, Shen L, Henderson AD et al.. “Asymptomatic vs Symptomatic Hypotension With Sacubitril/Valsartan in Heart Failure and Reduced Ejection Fraction in PARADIGM-HF.” Journal of the American College of Cardiology (2024). PMID: 39320292 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  158. [158]

    Packer M, Ferreira JP, Butler J et al.. “Reaffirmation of Mechanistic Proteomic Signatures Accompanying SGLT2 Inhibition in Patients With Heart Failure: A Validation Cohort of the EMPEROR Program.” Journal of the American College of Cardiology (2024). PMID: 39217550 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  159. [159]

    Patel-Murray NL, Zhang L, Claggett BL et al.. “Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic Substudy.” Journal of the American Heart Association (2024). PMID: 38904251 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  160. [160]

    Rascher J, Cotton D, Haertter S et al.. “Clinical pharmacokinetics and pharmacodynamics of empagliflozin in patients with heart failure.” British journal of clinical pharmacology (2024). PMID: 38852615 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  161. [161]

    Kondo T, Jhund PS, Gasparyan SB et al.. “A hierarchical kidney outcome using win statistics in patients with heart failure from the DAPA-HF and DELIVER trials.” Nature medicine (2024). PMID: 38710952 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  162. [162]

    Yang M, Kondo T, Talebi A et al.. “Dapagliflozin and quality of life measured using the EuroQol 5-dimension questionnaire in patients with heart failure with reduced and mildly reduced/preserved ejection fraction.” European journal of heart failure (2024). PMID: 38700986 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  163. [163]

    Chatur S, Neuen BL, Claggett BL et al.. “Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure.” Journal of the American College of Cardiology (2024). PMID: 38588927 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  164. [164]

    Foà A, Vaduganathan M, Claggett BL et al.. “Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.” Journal of the American College of Cardiology (2024). PMID: 38537919 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  165. [165]

    Peikert A, Vaduganathan M, Claggett BL et al.. “Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER.” European journal of heart failure (2024). PMID: 38487939 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  166. [166]

    Dhingra NK, Verma S, Butler J et al.. “Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced.” JACC. Heart failure (2024). PMID: 37715769 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  167. [167]

    Packer M, Butler J, Zeller C et al.. “Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure.” Circulation (2023). PMID: 37621153 ↗

    L1RCTCited in: Landmark Trials and Key Evidence
  168. [168]

    Khan MS, Anker SD, Filippatos G et al.. “Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial.” Journal of cardiac failure (2023). PMID: 37558088 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  169. [169]

    Curtain JP, Adamson C, Docherty KF et al.. “Prevalent and Incident Anemia in PARADIGM-HF and the Effect of Sacubitril/Valsartan.” JACC. Heart failure (2023). PMID: 37407154 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  170. [170]

    Pinsino A, Carey MR, Husain S et al.. “The Difference Between Cystatin C- and Creatinine-Based Estimated GFR in Heart Failure With Reduced Ejection Fraction: Insights From PARADIGM-HF.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 37086965 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  171. [171]

    Butt JH, Docherty KF, Claggett BL et al.. “Dapagliflozin in Black and White Patients With Heart Failure Across the Ejection Fraction Spectrum.” JACC. Heart failure (2023). PMID: 36881399 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  172. [172]

    Tsutsui H, Momomura SI, Saito Y et al.. “Incidence and risk factors of hypotension-related adverse events among Japanese patients with heart failure receiving sacubitril/valsartan or enalapril: Results from the PARALLEL-HF study.” Journal of cardiology (2025). PMID: 39284545 ↗

    L2RCTCited in: Landmark Trials and Key Evidence
  173. [173]

    Wang X, Pu J, Wang G et al.. “Efficacy and safety analysis of angiotensin receptor neprilysin inhibition(ARNI)in patients with heart failure: a real-world retrospective study.” BMC cardiovascular disorders (2023). PMID: 37430227 ↗

    L3RCTCited in: Landmark Trials and Key Evidence
  174. [174]

    Pavlu L, Vicha M, Flasik J et al.. “A comparison of heart failure patients with reduced ejection fraction in the Moravian Midlands Registry with the LCZ696 patients in the Paradigm-HF trial.” Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia (2024). PMID: 36748670 ↗

    L3RCTCited in: Landmark Trials and Key Evidence
  175. [175]

    Khan MS, Segar MW, Usman MS et al.. “Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk.” JACC. Heart failure (2023). PMID: 37227388 ↗

    L2TRIAL_NONRANDOMCited in: Landmark Trials and Key Evidence
  176. [176]

    Van Tassell BW, Golino M, Canada JM et al.. “Resolution of Systemic Inflammation in Patients With Recently Decompensated Heart Failure With Reduced Ejection Fraction With and Without Interleukin-1 Blockade by Anakinra.” Circulation. Heart failure (2026). PMID: 41431894 ↗

    L1RCTCited in: Prognosis, Risk Stratification, and Palliative Care
  177. [177]

    Li Y, Mao T, Qu X et al.. “Efficacy and safety of Qiliqiangxin capsule as adjunctive therapy in heart failure with reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials.” Journal of ethnopharmacology (2026). PMID: 41500350 ↗

    L1SR_MA_RCTCited in: Prognosis, Risk Stratification, and Palliative Care

Revision History

All updates applied to this page

Loading revisions…